Search clinical trials for: ARC-T Cells

Total 15452 results

Peking University

Unknown

MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma

Lymphoma

China
Allife Medical Science and Technology Co., Ltd.

Unknown

Study of BCMA CAR-T in Multiple Myeloma

Relapsed and Refractory Multiple Myeloma
First Affiliated Hospital of Wenzhou Medical University
Shanghai First Song Therapeutics Co., Ltd

Not yet recruiting

The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases

Systemic Sclerosis | Sjogren's Syndrome | Antiphospholipid Syndrome | ANCA Associated Vasculitis | Systemic Lupus Erythematosus (SLE) | Inflammatory Myopathy

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

Systemic Scleroderma | Dermatomyositis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Sjogren's Syndrome | SLE (Systemic Lupus)

China
Changhai Hospital
UTC Therapeutics Inc.

Recruiting

Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urologic Neoplasms

CD70-positive Advanced Urologic Neoplasms

China
St. Jude Children's Research Hospital

Recruiting

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Glioblastoma | Central Nervous System Neoplasms | High Grade Glioma | Ependymoma | Medulloblastoma | Diffuse Midline Glioma, H3 K27M-Mutant | Atypical Teratoid/Rhabdoid Tumor

United States
Zhejiang University

Recruiting

Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica

Neuromyelitis Optica

China
Zhejiang University

Recruiting

Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis

Myasthenia Gravis

China
KK Women's and Children's Hospital
Singapore General Hospital

Recruiting

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR | B-cell Acute Lymphoblastic Leukemia | Large B-cell Lymphoma

Singapore
iCell Gene Therapeutics
iCar Bio Therapeutics

Not yet recruiting

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

High Risk Hematologic Malignancies | Relapsed and/or Refractory Acute Myeloid Leukemia

China
King's College Hospital NHS Trust

Recruiting

Autologous Tregs for Aplastic Anaemia (TIARA)

Aplastic Anemia

United Kingdom
Fudan University
KAEDI

Recruiting

NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Glioblastoma | Hepatocellular Carcinoma | Medulloblastoma | Colon Cancer

China
AffyImmune Therapeutics, Inc.

Recruiting

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

Anaplastic Thyroid Cancer | Relapsed/Refractory Poorly Differentiated Thyroid Cancer

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen

Acute Myeloid Leukemia

United States
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Refractory Multiple Myeloma | Multiple Myeloma in Relapse | Plasmacytoid; Lymphoma

China
Xuanwu Hospital, Beijing
Beijing Mario Biotech Company; Hebei Senlang BIotech Company; Beijing HuiNengAn...

Recruiting

Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas

Glioma | Malignant Glioma of Brain | Recurrence Tumor

China
Poitiers University Hospital

Active, not recruiting

Innate T Cells and TKI Discontinuation (TIBIOP-LMC)

Chronic Myeloid Leukemia

France
Memorial Sloan Kettering Cancer Center

Active, not recruiting

MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma

Multiple Myeloma

United States
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.

Active, not recruiting

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

China
Sinobioway Cell Therapy Co., Ltd.
The Second Hospital of Anhui Medical University

Active, not recruiting

Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia (EECNTL)

Leukemia

China
Fujian Medical University

Unknown

CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)

Relapsed/Refractory AML

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative Neoplasm

China
Shenzhen Geno-Immune Medical Institute

Unknown

Antigen-specific T Cells Against Lung Cancer

Lung Cancer

China
Wuhan Union Hospital, China
Wuhan Bio-Raid Biotechnology Co, Ltd. China

Unknown

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | NK/T-cell Lymphoma | Adult T-Cell Lymphoma/Leukaemia

China
Eureka Therapeutics Inc.
Duke University; Duke Clinical Research Institute

Terminated

Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma

Lymphomas Non-Hodgkin's B-Cell

United States
Chinese PLA General Hospital

Unknown

A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy

Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T ACI

China
Qingdao Central Hospital
Yake Biotechnology Ltd.

Unknown

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

Lymphoma, B-Cell | Leukemia, B-Cell | Minimal Disease, Residual

China
Sinobioway Cell Therapy Co., Ltd.

Unknown

Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer (EECSC)

Stomach Neoplasms

China
Roger Williams Medical Center

Suspended

Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning

Monitor Adverse Events

United States
Peking University
University of Florida

Unknown

CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)

Lymphomas

China, United States
H. Kim Lyerly
National Cancer Institute (NCI); National Institutes of Health (NIH)

Terminated

CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant Disease (CMV-BMT)

Allogeneic Stem Cell Transplantation

United States
VIRxSYS Corporation

Active, not recruiting

Safety and Efficacy of T Cell Genetic Immunotherapy for HIV

HIV Infection

United States
Wuhan Union Hospital, China

Not yet recruiting

Study of SYS6020 in BCMA-positive Multiple Myeloma

Multiple Myeloma
The Children's Hospital of Zhejiang University...
Chongqing Precision Biotech Co., Ltd

Recruiting

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | CAR-T Cell Therapy

China
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
University of Pennsylvania
Prostate Cancer Foundation

Recruiting

TmPSMA-02 in mCRPC

Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies

Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | T-cell Acute Lymphoblastic Leukemia | T Lymphoblastic Leukemia/Lymphoma

China
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Jiangnan University; The Affiliated Nanjing Drum Tower... and other collaborators

Recruiting

CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma

Refractory and Relapsed T Cell Lymphoma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor

Gastric Cancer | Lung Cancer | Osteosarcoma | Neuroblastoma
iCell Gene Therapeutics
The General Hospital of Western Theater Command; Peking University Shenzhen... and other collaborators

Recruiting

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative Neoplasm

China
Rapa Therapeutics LLC
Massachusetts General Hospital; Hackensack Meridian Health

Available

RAPA-501 Therapy for ALS EAP

Amyotrophic Lateral Sclerosis

United States
Children's Hospital Medical Center, Cincinnati
Hoxworth Blood Center

Active, not recruiting

Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant

Solid Organ Transplant | Viral Infection

United States
University of Pennsylvania

Completed

cMet CAR RNA T Cells Targeting Breast Cancer

Metastatic Breast Cancer | Triple Negative Breast Cancer

United States
Children's Hospital Medical Center, Cincinnati
Hoxworth Blood Center

Withdrawn

Viral Specific T-cells for Treatment of COVID-19

Viral Infection

United States
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
The First Affiliated Hospital with Nanjing Medical...

Unknown

XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects

Lymphoma, B-Cell | Leukemia, B-cell

China
Wuhan Union Hospital, China
Wuhan Bio-Raid Biotechnology Co., Ltd.

Unknown

Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
Xinqiao Hospital of Chongqing
Xuzhou Medical University; Shanghai Changzheng Hospital; Hrain Biotechnology...

Unknown

Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma (MeCAR)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Stage III Adult Diffuse Large Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Stage III Follicular Lymphoma | Stage...

China
Shanghai Tongji Hospital, Tongji University School...

Unknown

CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy

Lymphoma | Leukemia

China
Cell Medica Ltd
University College, London; Cell Therapy Catapult

Completed

WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study

Acute Myeloid Leukaemia | Chronic Myeloid Leukaemia

United Kingdom

Search clinical trials for: ARC-T Cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations